Answers are grounded in this paper and cite their sources.
Cost-effectiveness analysis indicates ribociclib may improve health outcomes in postmenopausal women with advanced breast cancer, suggesting better value than abemaciclib.
Ribociclib improves health outcomes with a modest impact on costs and is likely to be more cost-effective than abemaciclib for postmenopausal women requiring 1 L treatment of HR+/HER2- aBC from a Medicare perspective.
No takes yet. Share an insight, caveat, or question.
Tarantino et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: